Citations

Clear

4847 citation(s) found for "Yu, Eric".

The intraoperative accuracy of maxillary balloon dilation: a blinded trial
Jensen, Brett T., Holbrook, Eric H. , Chen, Philip G. , Luong, Amber , Marino, Michael J. , Yao, William C. , Holbrook, Eric H , Chen, Philip G , Yao, William C

Mayo Clinic

International Forum of Allergy & Rhinology | January 10, 2019 | Volume: 9 | Issue: 5 | Pages: 452-457

10.1002/alr.22286 | PMID 30629822 Get It

BackgroundBalloon sinus dilation (BSD) is a commonly performed sinus procedure in the United States. Several cadaveric studies have evaluated BSD accuracy and the maxillary sinus has consistently been shown to be the most challenging to cannulate. We designed an independent study to evaluate the intraoperative accuracy of maxillary sinus BSD.MethodsA prospective, single‐blinded trial evaluating the accuracy of maxillary sinus BSD was performed using 2 commercially available BSD systems (guidewire‐ and probe‐based systems) randomly assigned to patients undergoing endoscopic surgery for chronic rhinosinusitus without nasal polyps (CRSsNP) or a skullbase approach in patients without sinus disease. All patients underwent maxillary BSD followed by uncinectomy to reveal dilation of the natural maxillary sinus ostia. The recorded procedures were reviewed by 3 fellowship‐trained rhinologists from different institutions blinded to the BSD system utilized. The primary endpoint compared accuracy of maxillary BSD attempts. The secondary endpoint compared accuracy between the 2 systems.ResultsTwenty‐nine maxillary BSD procedures were performed in 18 patients (age range, 20‐79 years; mean, 51 years) without nasal polyposis undergoing maxillary antrostomy as part of a more extensive procedure. BSD was successful in 18 of 29 (62%) attempts and unsuccessful in 9 of 29 (31%) attempts, with statistically “almost perfect” interrater agreement (kappa = 0.86). There was no statistical difference between the 2 BSD systems (p = 0.81).ConclusionMaxillary BSD appeared to be less accurate in living patients when compared with findings from previously published cadaver studies. There were no differences in accuracy between the probe‐ and guidewire‐based systems. This is the first non‒industry‐sponsored study evaluating maxillary sinus BSD in living patients. Further studies are needed to investigate the clinical implications of our findings.
Probing the Virtual Proteome to Identify Novel Disease Biomarkers
Smith, J. G. , Melander, Olle , Ngo, Debby , Shaffer, Christian M., Ferguson, Jane F. , Herzig, Matthew , McCarty, Catherine A. , Jarvik, Gail P. , Gordon, Allan , Palmer, Melody R. , Crosslin, David R. , Larson, Eric B. , Pacheco, Jennifer A. , Peissig, Peggy , Brilliant, Murray H. , Kitchner, Terrie, Linneman, James G., Namjou, Bahram , Ritchie, Marylyn D. , Borthwick, Kenneth M., Kiryluk, Krzysztof , Mentch, Frank , Sleiman, Patrick , Karlson, Elizabeth W. , Zhu, Yineng, Denny, Joshua C. , Roden, Dan M. , Gerszten, Robert E. , Wang, Thomas J. , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Pacheco, Jennifer A , Kiryluk, Krzysztof , Ferguson, Jane F , Mosley, Jonathan D , Benson, Mark D. , Chute, Christopher G. , Carrell, David , Kullo, Iftikhar J. , Williams, Marc S , Verma, Shefali S. , Vasan, Ramachandran S. , Yang, Qiong , Roden, Dan M. , Smith, J Gustav

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 22 | Pages: 2469-2481

10.1161/circulationaha.118.036063 | PMID 30571344 Get It

Background: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a “virtual proteomic” approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals. Methods: We used genome-wide association data from the Framingham Heart Study (n=759) to construct genetic predictors for 1129 plasma protein levels. We validated the genetic predictors for 268 proteins and used them to compute predicted protein levels in 41 288 genotyped individuals in the Electronic Medical Records and Genomics (eMERGE) cohort. We tested associations for each predicted protein with 1128 clinical phenotypes. Lead associations were validated with directly measured protein levels and either low-density lipoprotein cholesterol or subclinical atherosclerosis in the MDCS (Malmö Diet and Cancer Study; n=651). Results: In the virtual proteomic analysis in eMERGE, 55 proteins were associated with 89 distinct diagnoses at a false discovery rate q<0.1. Among these, 13 associations involved lipid (n=7) or atherosclerosis (n=6) phenotypes. We tested each association for validation in MDCS using directly measured protein levels. At Bonferroni-adjusted significance thresholds, levels of apolipoprotein E isoforms were associated with hyperlipidemia, and circulating C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β predicted subclinical atherosclerosis. Odds ratios for carotid atherosclerosis were 1.31 (95% CI, 1.08–1.58; P =0.006) per 1-SD increment in C-type lectin domain family 1 member B and 0.79 (0.66–0.94; P =0.008) per 1-SD increment in platelet-derived growth factor receptor-β. Conclusions: We demonstrate a biomarker discovery paradigm to identify candidate biomarkers of cardiovascular and other diseases.
A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma.
Martin, Thomas G. , Hsu, Karl , Glenn, Martha, Strickland, Stephen Anthony , Mıkhael, Joseph , Charpentier, Éric

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 8532-8532

10.1200/jco.2014.32.15_suppl.8532 Get It

A phase 2 study of 99m Tc-trofolastat chloride (MIP-1404) SPECT/CT to identify and localize prostate cancer (PCa) in high-risk patients (pts) undergoing radical prostatectomy (RP) and extended pelvic lymph node (ePLN) dissection compared to hist
Slawin, Kevin M., Tenke, Péter , Joniau, Steven , Ellis, William J., Buzogány, István, Мишугин, С. В. , Stolz, Josef, Матвеев, В. Б. , Karnes, R. Jeffrey , Jarrard, David Frasier, Yuh, Bertram, Trabulsi, Edouard J. , Stambler, Nancy , Armor, Thomas, Israel, Robert J. , Joniau, Steven , Alekseev, B. Yа. , Klein, Eric A. , Študent, Vladimír , Scherr, Douglas S. , Babich, John W.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16003-e16003

10.1200/jco.2014.32.15_suppl.e16003 Get It

Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP).
Renfro, Lindsay A. , Haller, Daniel G. , Loprinzi, Charles L. , Twelves, Chris, Group, Adjuvant Colon Cancer Endpoints (ACCENT), Grothey, Axel , Kerr, David , André, Thierry , Cutsem, Eric Van , Saltz, Leonard B. , Labianca, Roberto , Alberts, Steven R. , Schmoll, Hans‐Joachim , Yothers, Greg , Sargent, Daniel J. , Group, Adjuvant Colon Cancer Endpoints (ACCENT)

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3601-3601

10.1200/jco.2014.32.15_suppl.3601 Get It

Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial.
Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith , Asmann, Yan W. , Eckel‐Passow, Jeanette E. , Tenner, Kathleen , Jen, Jin , Fan, Jian‐Bing , Geiger, Xochiquetzal J., McCullough, Ann E. , Chen, Beiyun, Zschunke, Michael A., Jenkins, Robert B. , Reinholz, Monica M., Kalari, Krishna R. , Dueck, Amylou C. , Sledge, George W. , Winer, Eric P. , Gralow, Julie R. , Ballman, Karla V.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 509-509

10.1200/jco.2014.32.15_suppl.509 Get It

TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).
Gelman, Rebecca , Krop, Ian E. , Melisko, Michelle , Agar, Nathalie Y.R. , Blackwell, Kimberly , Connolly, Roisín M. , Poznak, Catherine Van , Puhalla, Shannon, Ryabin, Nicole, Lawler, Elizabeth S, Ibrahim, Nuhad K. , Liu, Minetta C. , Agar, Nathalie Y R , Freedman, Rachel A. , Wefel, Jeffrey S. , Lowe, Alarice Cheng-Yi , Niravath, Polly Ann , Wolff, Antonio C. , Winer, Eric P. , Lin, Nancy U.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 528-528

10.1200/jco.2014.32.15_suppl.528 Get It

A tool to predict post-transcriptional instability related to the dysregulation of the SETD2 histone methyltransferase in renal cell carcinoma (RCC).
Champion, Mia D., Yan, Huihuang , Evans, Jared M., Nie, Jeff, Moore, Raymond M. , Ördög, Tamás , Zhang, Zhiguo , Stewart, A. Keith, Kocher, Jean‐Pierre , Zhang, Zhiguo , Lee, Jeong‐Heon , Davila, Jaime , Joseph, Richard W. , Jonasch, Eric W. , Ho, Thai H.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11072-11072

10.1200/jco.2014.32.15_suppl.11072 Get It

A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Aggarwal, Rahul , Weinberg, Vivian, Ryan, Charles J. , Harzstark, Andrea, Derleth, Christina Louise, Lowe, Kimberly A. , Bryce, Alan H. , Small, Eric J.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e16060-e16060

10.1200/jco.2014.32.15_suppl.e16060 Get It

Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
Wagle, Nikhil , Richardson, Andrea L. , Forero‐Torres, Andres , Hobday, Timothy J. , Dees, Elizabeth Claire , Nanda, Rita , Rimawi, Mothaffar F. , Barry, William T., Gabriel, Stacey B., Garraway, Levi A. , Krop, Ian E. , Rimawi, Mothaffar , Lin, Nancy U. , Leshchiner, Ignaty , Mayer, Ingrid A. , Wolff, Antonio C. , Winer, Eric P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 536-536

10.1200/jco.2014.32.15_suppl.536 Get It